IMARA Inc. (IMRA) |
|
6.32 0.87 (15.96%)
|
02-23 16:00 |
|
Open: |
5.21 |
Pre. Close: |
5.45 |
|
High:
|
6.32 |
Low:
|
5.18 |
|
Volume:
|
271,721 |
Market Cap:
|
166(M) |
|
|
|
Technical analysis |
as of: 2023-03-03 4:50:22 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 7.38 One year: 8.62 |
| Support: |
Support1: 4.82 Support2: 3.9 |
| Resistance: |
Resistance1: 6.32 Resistance2: 7.38 |
| Pivot: |
5.3 |
| Moving Average: |
MA(5): 5.49 MA(20): 5.07
MA(100): 4.25 MA(250): 2.54 |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 87.2 %D(3): 81.4 |
| RSI: |
RSI(14): 75.3 |
| 52-week: |
High: 6.32 Low: 0.97 |
| Average Vol(K): |
3-Month: 114 (K) 10-Days: 119 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMRA ] has closed Bollinger Bands are 9.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.32 - 6.34 |
6.34 - 6.36 |
|
Low:
|
5.13 - 5.15 |
5.15 - 5.17 |
|
Close:
|
6.27 - 6.31 |
6.31 - 6.35 |
|
Company Description |
|
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. |
Headline News |
Wed, 15 Mar 2023
An army of Big Pharma companies is backing new startup out of ... - The Business Journals
Wed, 22 Feb 2023
Imara Announces Stockholder Approval of Merger With Enliven - GlobeNewswire
Fri, 06 Jan 2023
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch - Penny Stocks
Fri, 14 Oct 2022
SHAREHOLDER ALERT: Weiss Law Investigates IMARA Inc. - KALB
Thu, 13 Oct 2022
Dow Futures Tick Higher After Indices Stage Major Reversal - Yahoo Finance
Thu, 13 Oct 2022
Enliven Therapeutics and Imara Announce Merger Agreement - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
26 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
16.6 (%) |
|
% Held by Institutions
|
71.3 (%) |
|
Shares Short
|
341 (K) |
|
Shares Short P.Month
|
1,370 (K) |
Stock Financials |
|
EPS
|
-2.5 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.77 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-34.2 |
|
Return on Equity (ttm)
|
-57.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.71 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-46 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-2.54 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.67 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-3.6 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
